Recent guidelines have reported that a combination of aromatase inhibitor and cyclin4/6-dependent kinase inhibitors (CDKIs) is the preferred FLx for HR-positive/HER2-negative BC (35). The gene discussed is CYP19A1; the disease is breast cancer.